Cytokinetics, Inc. Retains Favorable Outlook with New Heart Disease Study Data

Cytokinetics, Inc. showcases new data from ongoing heart disease study, reporting significant reductions in left ventricular outflow tract gradient and positive outcomes in NT-proBNP, cardiac structure, and function. Mizuho reiterates Buy rating with a steady price target of $99.00.